ACEi/ARB and Deaths of COVID-19 Patients

被引：6
作者：
Azad, Gulam Navi [1 ]
Kumar, Anoop [2 ,3 ]
机构：
[1] Natl Inst Pharmaceut Educ & Res NIPER, Dept Pharmacol & Toxicol, Lucknow, UP, India
[2] Delhi Pharmaceut Sci & Res Univ DPSRU, Dept Pharmacol, New Delhi, India
[3] Delhi Pharmaceut Sci & Res Univ DPSRU, Dept Pharmacol, New Delhi 110017, India
来源：
CURRENT HYPERTENSION REVIEWS | 2022年 / 18卷 / 02期
关键词：
COVID-19; Angiotensin-converting enzyme inhibitor (ACEI); Angiotensin-receptor blocker (ARB); mortality; Rev Man 5; odd ratio; SYSTEM INHIBITORS; ANGIOTENSIN;
D O I：
10.2174/1573402118666220407093332
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
The practice of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) in COVID-19 hypertensive patients is still an open question for clinicians to answer. The present study was conducted to find out the association between the use of ACEI/ARB and the mortality rate of COVID-19 patients. The search was conducted from December 2019 to October 2020 in PubMed to identify relevant published studies. RevMan 5 was used for the analysis of the data. The random-effect model was used to calculate the odds ratio. In total, 07 studies were found to be appropriate, reporting a total of 1,566 subjects. The odds ratio was found to be 0.86 [0.41, 1.81], indicating no association between ACEI/ARB and the mortality rate of COVID-19 patients. In conclusion, we may suggest continuing the use of ACEi/ARB in COVID-19 patients till further pieces of evidence are generated.
引用
收藏
页码：158 / 162
页数：5
相关论文
共 17 条
[1]   The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies-reply [J].
Albini, Adriana ;
Noonan, Douglas McClain ;
Pelosi, Giuseppe ;
Di Guardo, Giovanni ;
Lombardo, Michele .
INTERNAL AND EMERGENCY MEDICINE, 2020, 15 (08) :1583-1584
[2]   Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia A Case Series Study [J].
Andrea, Conversano ;
Francesco, Melillo ;
Antonio, Napolano ;
Evgeny, Fominskiy ;
Marzia, Spessot ;
Fabio, Ciceri ;
Eustachio, Agricola .
HYPERTENSION, 2020, 76 (02) :E10-E12
[3]   Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives [J].
Felice, Carla ;
Nardin, Chiara ;
Di Tanna, Gian Luca ;
Grossi, Ugo ;
Bernardi, Enrico ;
Scaldaferri, Luca ;
Romagnoli, Micaela ;
Tonon, Luca ;
Cavasin, Paola ;
Novello, Simone ;
Scarpa, Riccardo ;
Farnia, Antonio ;
De Menis, Ernesto ;
Rigoli, Roberto ;
Cinetto, Francesco ;
Pauletto, Paolo ;
Agostini, Carlo ;
Rattazzi, Marcello .
AMERICAN JOURNAL OF HYPERTENSION, 2020, 33 (10) :944-948
[4]   Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study [J].
Gao, Chao ;
Cai, Yue ;
Zhang, Kan ;
Zhou, Lei ;
Zhang, Yao ;
Zhang, Xijing ;
Li, Qi ;
Li, Weiqin ;
Yang, Shiming ;
Zhao, Xiaoyan ;
Zhao, Yuying ;
Wang, Hui ;
Liu, Yi ;
Yin, Zhiyong ;
Zhang, Ruining ;
Wang, Rutao ;
Yang, Ming ;
Hui, Chen ;
Wijns, William ;
McEvoy, J. William ;
Soliman, Osama ;
Onuma, Yoshinobu ;
Serruys, Patrick W. ;
Tao, Ling ;
Li, Fei .
EUROPEAN HEART JOURNAL, 2020, 41 (22) :2058-2066
[5]   Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) [J].
Guo, Tao ;
Fan, Yongzhen ;
Chen, Ming ;
Wu, Xiaoyan ;
Zhang, Lin ;
He, Tao ;
Wang, Hairong ;
Wan, Jing ;
Wang, Xinghuan ;
Lu, Zhibing .
JAMA CARDIOLOGY, 2020, 5 (07) :811-818
[6]   SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [J].
Hoffmann, Markus ;
Kleine-Weber, Hannah ;
Schroeder, Simon ;
Krueger, Nadine ;
Herrler, Tanja ;
Erichsen, Sandra ;
Schiergens, Tobias S. ;
Herrler, Georg ;
Wu, Nai-Huei ;
Nitsche, Andreas ;
Mueller, Marcel A. ;
Drosten, Christian ;
Poehlmann, Stefan .
CELL, 2020, 181 (02) :271-+
[7]   Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China [J].
Li, Juyi ;
Wang, Xiufang ;
Chen, Jian ;
Zhang, Hongmei ;
Deng, Aiping .
JAMA CARDIOLOGY, 2020, 5 (07) :825-830
[8]  
Liberati A, 2009, BMJ-BRIT MED J, V339, DOI [10.1016/j.ijsu.2010.02.007, 10.1371/journal.pmed.1000097, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.b2535, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]
[9]   EMERGING ROLE OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS IN CARDIAC AND VASCULAR PROTECTION [J].
LONN, EM ;
YUSUF, S ;
JHA, P ;
MONTAGUE, TJ ;
TEO, KK ;
BENEDICT, CR ;
PITT, B .
CIRCULATION, 1994, 90 (04) :2056-2069
[10]   Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension [J].
Meng, Juan ;
Xiao, Guohui ;
Zhang, Juanjuan ;
He, Xing ;
Ou, Min ;
Bi, Jing ;
Yang, Rongqing ;
Di, Wencheng ;
Wang, Zhaoqin ;
Li, Zigang ;
Gao, Hong ;
Liu, Lei ;
Zhang, Guoliang .
EMERGING MICROBES & INFECTIONS, 2020, 9 (01) :757-760
12